A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and immune response to daily sublingual
(under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with
peanut allergies.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)